Arthur M. Cohen & Associates’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Arthur M. Cohen & Associates’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-36,500	Closed	-$5.33M	–	126
2019 Q4	$5.33M	Hold	36,500	–	–	1.64%	15
2019 Q3	$5.47K	Sell	36,500 -27,890	-43%	-$5.03K	1.54%	15
2019 Q2	$10K	Buy	+64,390	New	+$13K	﹤0.01%	116
2019 Q1	–	Sell	-31,390	Closed	-$38.6K	–	117
2018 Q4	$38.6K	Hold	31,390	–	–	12.28%	1
2018 Q3	$38.6K	Buy	+31,390	New	+$35.1K	11.75%	1
2017 Q2	$42K	Buy	+31,390	New	+$45.4K	0.02%	98

Arthur M. Cohen & Associates's GNMX Position: Q1 2020 in Review

Arthur M. Cohen & Associates sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 36,500 shares — an estimated $5.33M sold.

Arthur M. Cohen & Associates first reported a position in GNMX in Q2 2017 and held it in 6 quarters. The position peaked at $5.33M in Q4 2019. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.

Arthur M. Cohen & Associates reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
Arthur M. Cohen & Associates sold 36,500 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $5.33M.
Arthur M. Cohen & Associates first reported a position in Aevi Genomic Medicine Inc in Q2 2017 and held it in 6 quarters.
Arthur M. Cohen & Associates's Aevi Genomic Medicine Inc position peaked at $5.33M in Q4 2019.
2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.

Based on Arthur M. Cohen & Associates's 13F filing for Q1 2020, filed 14 Apr 2020.